Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESLA NASDAQ:KZR NASDAQ:SNYR NASDAQ:TSBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESLAEstrella Immunopharma$0.86+2.9%$0.93$0.63▼$1.78$30.38M0.3417,556 shs10,927 shsKZRKezar Life Sciences$4.05-5.2%$4.39$3.62▼$9.18$31.20M0.6572,386 shs67,095 shsSNYRSynergy CHC$3.36-2.9%$2.83$0.36▼$10.00$31.81MN/A54,733 shs29,375 shsTSBXTurnstone Biologics$0.35-0.9%$0.35$0.29▼$2.47$8.18M1.3590,432 shs82,535 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESLAEstrella Immunopharma+2.86%-4.21%-1.93%-25.52%-44.62%KZRKezar Life Sciences-5.15%-6.03%-9.80%-10.00%-37.69%SNYRSynergy CHC-2.89%-11.35%+3.70%+57.75%+3,260.00%TSBXTurnstone Biologics-0.93%-2.72%-2.75%+0.06%-85.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationESLAEstrella Immunopharma2.941 of 5 stars3.55.00.00.02.61.70.0KZRKezar Life Sciences3.5395 of 5 stars3.21.00.04.60.03.30.6SNYRSynergy CHC3.8798 of 5 stars3.80.00.00.03.33.31.9TSBXTurnstone Biologics1.9432 of 5 stars2.83.00.00.00.02.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESLAEstrella Immunopharma 3.00Buy$16.001,751.85% UpsideKZRKezar Life Sciences 2.33Hold$39.50875.31% UpsideSNYRSynergy CHC 3.50Strong Buy$10.00197.62% UpsideTSBXTurnstone Biologics 1.50Reduce$0.4528.50% UpsideCurrent Analyst Ratings BreakdownLatest TSBX, SNYR, KZR, and ESLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025KZRKezar Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/29/2025ESLAEstrella ImmunopharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESLAEstrella ImmunopharmaN/AN/AN/AN/A$0.12 per shareN/AKZRKezar Life Sciences$7M4.23N/AN/A$16.02 per share0.25SNYRSynergy CHC$34.83M0.89$0.26 per share13.01($1.91) per share-1.76TSBXTurnstone BiologicsN/AN/AN/AN/A$1.36 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESLAEstrella Immunopharma-$7.31M-$0.26N/A∞N/AN/A-1,132.38%-273.91%N/AKZRKezar Life Sciences-$83.74M-$10.82N/AN/AN/AN/A-61.15%-50.27%8/12/2025 (Estimated)SNYRSynergy CHC$2.12MN/A0.005.69N/AN/A-8.48%12.75%N/ATSBXTurnstone Biologics-$70.84M-$2.73N/AN/AN/AN/A-162.79%-124.10%8/13/2025 (Estimated)Latest TSBX, SNYR, KZR, and ESLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025TSBXTurnstone Biologics-$0.16N/AN/AN/AN/AN/A8/12/2025Q2 2025KZRKezar Life Sciences-$2.25N/AN/AN/AN/AN/A5/15/2025Q1 2025SNYRSynergy CHC$0.07$0.10+$0.03$0.10$9.03 million$8.17 million5/13/2025Q1 2025KZRKezar Life Sciences-$2.56-$2.27+$0.29-$2.27N/AN/A5/8/2025Q1 2025TSBXTurnstone Biologics-$0.26-$0.51-$0.25-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/ASNYRSynergy CHCN/AN/AN/AN/AN/ATSBXTurnstone BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESLAEstrella ImmunopharmaN/A0.220.22KZRKezar Life Sciences0.047.097.09SNYRSynergy CHCN/A1.911.62TSBXTurnstone BiologicsN/A3.703.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESLAEstrella Immunopharma0.35%KZRKezar Life Sciences67.90%SNYRSynergy CHCN/ATSBXTurnstone Biologics52.51%Insider OwnershipCompanyInsider OwnershipESLAEstrella Immunopharma55.10%KZRKezar Life Sciences10.40%SNYRSynergy CHC56.60%TSBXTurnstone Biologics32.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESLAEstrella ImmunopharmaN/A36.17 million16.24 millionNot OptionableKZRKezar Life Sciences607.31 million6.55 millionNot OptionableSNYRSynergy CHC409.19 million3.99 millionN/ATSBXTurnstone Biologics8223.14 million15.71 millionNot OptionableTSBX, SNYR, KZR, and ESLA HeadlinesRecent News About These Companies$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Turnstone Biologics Corp. (NASDAQ: TSBX)June 30, 2025 | globenewswire.comTurnstone Biologics Corp. Enters Merger Agreement with XOMAJune 27, 2025 | tipranks.comXOMA stock rises after acquisition of Turnstone BiologicsJune 27, 2025 | au.investing.comTurnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment SlumpsJune 27, 2025 | msn.comTSBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Turnstone Biologics Corp. Is Fair to ShareholdersJune 27, 2025 | businesswire.comTurnstone Biologics Corp. (TSBX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comTurnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent ...May 8, 2025 | gurufocus.comTurnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate HighlightsMay 8, 2025 | globenewswire.comTurnstone Biologics reports Q4 EPS (56c) vs (73c) last yearMarch 31, 2025 | markets.businessinsider.comTurnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 28, 2025 | investing.comTurnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 28, 2025 | globenewswire.comTurnstone Biologics stock plunges to 52-week low of $0.4February 11, 2025 | msn.comTurnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?February 7, 2025 | zacks.comTurnstone Biologics to explore strategic alternativesFebruary 6, 2025 | thepharmaletter.comTTurnstone ends last remaining clinical program due to costs, plots more layoffsFebruary 5, 2025 | fiercebiotech.comFTurnstone Biologics halts TIDAL-01 development, seeks alternativesFebruary 5, 2025 | msn.comTurnstone Biologics downgraded to Neutral from Overweight at Piper SandlerFebruary 5, 2025 | markets.businessinsider.comTurnstone Biologics Corp (TSBX) Stock: A Deeper Look at Its True PotentialFebruary 5, 2025 | bovnews.comBTurnstone Biologics Corp. Discontinues TIDAL-01 Clinical Studies and Initiates Strategic Alternatives ReviewFebruary 4, 2025 | quiverquant.comQTurnstone Biologics Announces Plans to Explore Strategic AlternativesFebruary 4, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTSBX, SNYR, KZR, and ESLA Company DescriptionsEstrella Immunopharma NASDAQ:ESLA$0.86 +0.02 (+2.86%) Closing price 08/1/2025 03:58 PM EasternExtended Trading$0.86 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Kezar Life Sciences NASDAQ:KZR$4.05 -0.22 (-5.15%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.04 -0.01 (-0.37%) As of 08/1/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Synergy CHC NASDAQ:SNYR$3.36 -0.10 (-2.89%) As of 08/1/2025 04:00 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.Turnstone Biologics NASDAQ:TSBX$0.35 0.00 (-0.93%) Closing price 08/1/2025 03:47 PM EasternExtended Trading$0.35 +0.00 (+0.51%) As of 08/1/2025 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
